SEMA3C and breast carcinoma: To assess its drugability potential within ER+ breast cancer, we conducted proof-of-concept testing using B1SP, a novel SEMA3C pathway inhibitor, to lay the groundwork for the development of SEMA3C-targeted therapies in ER+ breast cancer.